CClinicalTrials.gg
CompletedNCT03942250Updated Sep 21, 2023

Uses of Irradiated Human Amniotic Membrane in the Treatment of Dystrophic Epidermolysis Bullosa Patients

An interventional study of REGE pro dressing in Epidermolysis Bullosa and Chronic Skin Ulcer, sponsored by Egyptian Atomic Energy Authority. Completed at 1 site in Egypt. Open to participants aged 12 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-21.

Sponsored by Egyptian Atomic Energy Authority · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
12 Years to 45 Years
Sex
All
01

Study summary

To evaluate the effect of human amniotic membrane as a weekly dressing on chronic wounds in Epidermolysis Bullosa (EB) patients.

Read the detailed description

Dried human amniotic membrane dressing were obtained from National center for radiation research and technology, Egypt (NCRRT), under commercial name REGE pro.

02

Conditions studied

  • Epidermolysis Bullosa
  • Chronic Skin Ulcer

Keywords

  • Epidermolysis Bullosa
  • Amniotic membrane
03

Who can participate

Ages eligible
12 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

1- Patients diagnosed as EB wounds must be chronic

Exclusion criteria

Exclusion Criteria:

  1. Patients Must stop other line of treatment
  2. Exclude patients have:

    1. Autoimmune diseases
    2. Diabetes
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Treated

    Patients who received REGE pro dressing on EB wounds lesion weekly for 10 weeks

    Biological: REGE pro dressing

Interventions

  • BiologicalREGE pro dressing

    REGE pro is a dressing of dried human amniotic membrane sterilized by gamma radiation

05

What researchers measure

Primary outcomes

  1. Lesion area

    The lesion area from the first treatment is greater than 2 cm\^2 (grade 3, according to CTCAE v4.0), to the complete healing (= 0 cm\^2).

    Time frame: 6 weeks

  2. Clinical progression sings

    * After the first application time: White transperent color of granulation tissue appeared. * After the second application time: color dense of granulation tissue increased and covered all over the wound. * After the third application time: granulation tissue thickness increased and appeared as a complete homogenous layer. * After the fourth application time: depending on lesion depth and size, granulation tissue turned to be pink to red color. * After the fifth and sexth application time: Skin layers development appeared.

    Time frame: 6 weeks

Secondary outcomes

  1. Patient complain (upon the weekly questionnaire)

    The quality of life is scored 0 (minimum) -100 (maximum), the pain reduction is scored 0-100 (as previous) from the first visit till 6 weeks.

    Time frame: 6 weeks

06

Study locations

1 site
  • Amniotic tissue lab
    Cairo, 29, Egypt
07

References and documents

Publications

  • Nemr W, Bashandy AS, Araby E, Khamiss O. Biological Activity Alterations of Human Amniotic Membrane Pre and Post Irradiation Tissue Banking. Pak J Biol Sci. 2016;19(7):289-298. doi: 10.3923/pjbs.2016.289.298. PubMed 29023030 ↗
  • Lo V, Lara-Corrales I, Stuparich A, Pope E. Amniotic membrane grafting in patients with epidermolysis bullosa with chronic wounds. J Am Acad Dermatol. 2010 Jun;62(6):1038-44. doi: 10.1016/j.jaad.2009.02.048. PubMed 20466177 ↗
08

Registry details

Key details

Study ID
NCT03942250
Lead sponsor
Egyptian Atomic Energy Authority
Collaborators
Waleed Nemr,Egyptian Atomic Energy Authority
Responsible party
Nashwa Radwan (Head of amniotic tissue laboratory, Principal Investigator, Egyptian Atomic Energy Authority) — Principal investigator
First posted
May 8, 2019
Start date
Jan 2017
Primary completion
Dec 2017
Completion
Feb 2019
Last update
Sep 21, 2023

Study contacts

Nashwa K Radwan, PhD
study director · NATIONAL CENTER FOR RADIATION RESEARCH AND TECHNOLOGY

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion